TEM Jumps On Upbeat Revenue, Raised Outlook, ARK Buy Pre-Earnings

 

• Tempus raised the lower end of its full-year revenue guidance to $1.60 billion from $1.595 billion.

• The company's data licensing bookings exceeded $550 million year to date following its October collaboration with Bristol Myers Squibb.

• Cathie Wood's ARK Invest purchased 154,521 Tempus shares through two ETFs, ahead of earnings.

https://finance.yahoo.com/healthcare/articles/tem-stock-jumps-upbeat-revenue-131451094.html